MedTrace Logo

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

NCT07165132 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2026-04-13

No results posted yet for this study

Summary

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Conditions

  • GEP-NET
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Gastroenteropancreatic Neuroendocrine Tumor Disease
  • Neuroendocrine Tumors
  • Carcinoid
  • Carcinoid Tumor
  • Pancreatic NET
  • Solid Tumor
  • Somatostatin Receptor

Interventions

DRUG

RYZ401

Ac-225

Sponsors & Collaborators

  • RayzeBio, Inc.

    lead INDUSTRY

Principal Investigators

  • Ye Yuan, MD · RayzeBio, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-03
Primary Completion
2027-02-28
Completion
2033-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07165132 on ClinicalTrials.gov